Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety Study of Epidiolex for Chronic Liver Injury
NCT05044819Phase 4Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cannabidiol in Lennox-Gastaut syndrome (LGS), Dravet syndrome, tuberous sclerosis complex (TSC), sponsored by Jazz Pharmaceuticals plc. Started Jul 2021; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
Lennox-Gastaut syndrome (LGS)Dravet syndrometuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NCT05044819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044819.